Compare ORA & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORA | BLTE |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.0B |
| IPO Year | 2004 | 2021 |
| Metric | ORA | BLTE |
|---|---|---|
| Price | $103.10 | $151.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | $127.82 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 729.8K | 147.0K |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.44% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.14 | N/A |
| Revenue | ★ $719,267,000.00 | N/A |
| Revenue This Year | $16.52 | N/A |
| Revenue Next Year | $3.64 | $492.11 |
| P/E Ratio | $92.04 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $89.08 | $62.18 |
| 52 Week High | $146.39 | $200.00 |
| Indicator | ORA | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 44.35 |
| Support Level | $100.84 | $146.94 |
| Resistance Level | $115.65 | $161.17 |
| Average True Range (ATR) | 2.87 | 7.15 |
| MACD | -0.49 | -1.67 |
| Stochastic Oscillator | 3.14 | 4.70 |
Ormat Technologies Inc is engaged in the geothermal and recovered energy power business. It is engaged in three business segments: the Electricity Segment. where the company develops, builds, owns, and operates geothermal, solar PV, and recovered energy-based power plants in the United States and geothermal power plants in other countries and sells the electricity generated. Product Segment includes designing, manufacturing, and selling equipment for geothermal and recovered energy-based electricity generation and providing services relating to the engineering, procurement, and construction of geothermal & recovered energy-based power plants. Energy Storage Segment includes owning & operating grid-connected which provide capacity, energy, & ancillary services directly to the electric grid.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.